Risk of cardio-nephro-metabolic disease from NAFLD to MAFLD: fact or fiction?

Abstract

Nonalcoholic fatty liver disease (NAFLD) is emerging as the most common etiology for chronic liver disease. Despite this, our understanding of this illness is lacking. The previous paradigm is that central adiposity, hyperlipidemia, hypertension, and insulin resistance, also known as metabolic syndrome, lead to NAFLD, and this relationship is unidirectional. However, recent evidence clearly shows that the clinical burden of this illness extends well beyond liver-related morbidity and mortality and is associated with multiple extrahepatic complications, particularly metabolic consequences. Due to this, the professional consensus has proposed using the term metabolic associated fatty liver disease (MAFLD) to more accurately reflect pathogenesis and help in patient stratification for management. This review discusses the shared pathophysiological mechanisms that link these diseases and how this can be leveraged to prevent these complications in individuals with NAFLD/MAFLD.

Keywords

Nonalcoholic fatty liver disease / metabolic associated fatty liver disease / cardiovascular disease / diabetes / insulin resistance / chronic kidney disease

References

[1] Chalasani N,Lavine JE.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases.Hepatology2018;67:328-57

[2] Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol2016;64:1388-402

[3] Younossi Z,Marietti M.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2018;15:11-20

[4] Lazo M,Eberhardt MS.Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994.Am J Epidemiol2013;178:38-45 PMCID:PMC3698993

[5] Masarone M,Abenavoli L,Persico M.Non alcoholic fatty liver: epidemiology and natural history.Rev Recent Clin Trials2014;9:126-33

[6] Anstee QM,Day CP.Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.Nat Rev Gastroenterol Hepatol2013;10:330-44

[7] Eslam M,George J.International Consensus PanelMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology2020;158:1999-2014.e1

[8] Mantovani A,Bonora E.Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis.Diabetes Care2018;41:372-82

[9] Ekstedt M,Mathiesen UL.Long-term follow-up of patients with NAFLD and elevated liver enzymes.Hepatology2006;44:865-73

[10] Moschen AR,Tilg H.Adiponectin: key player in the adipose tissue-liver crosstalk.Curr Med Chem2012;19:5467-73

[11] Tilg H.Adipocytokines: mediators linking adipose tissue, inflammation and immunity.Nat Rev Immunol2006;6:772-83

[12] Zhang H,Gu H.Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease.J Clin Lab Anal2019;33:e22709 PMCID:PMC6818611

[13] Khan RS,Cusi K.Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.Hepatology2019;70:711-24

[14] Chen CC,Chen JJ.Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells.Mol Pharmacol2001;59:493-500

[15] Pedersen HK,Nielsen HB.MetaHIT ConsortiumHuman gut microbes impact host serum metabolome and insulin sensitivity.Nature2016;535:376-81

[16] Boursier J,Barret M.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.Hepatology2016;63:764-75 PMCID:PMC4975935

[17] Han R,Li H.Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.Front Med2018;12:645-57

[18] Vrieze A,Holleman F.Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.Gastroenterology2012;143:913-6.e7

[19] Masarone M,Dallio M.Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease.Oxid Med Cell Longev2018;2018:1-14 PMCID:PMC6016172

[20] Patterson RE,Williams CM.Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity.Am J Physiol Endocrinol Metab2016;310:E484-94 PMCID:PMC4824140

[21] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[22] Targher G,Padovani R.Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.Diabetes Care2007;30:1212-8

[23] Targher G,Rodella S.Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients.Diabetologia2008;51:444-50

[24] Targher G,Chonchol M.Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients.Diabetologia2010;53:1341-8

[25] Williamson RM,Glancy S.Edinburgh Type 2 Diabetes Study InvestigatorsPrevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.Diabetes Care2011;34:1139-44 PMCID:PMC3114489

[26] Zsóri G,Ivány E.In New-onset diabetes mellitus, metformin reduces fat accumulation in the liver, but not in the pancreas or pericardium.Metab Syndr Relat Disord2019;17:289-95

[27] Brandt A,Kehm R.Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine.Sci Rep2019;9:6668 PMCID:PMC6491483

[28] Handzlik G,Kozaczka J.Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease.Pharmacol Rep2019;71:183-8

[29] Musso G,Rosina F.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Diabetologia2012;55:885-904

[30] Sawangjit R,Phisalprapa P.Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis.Medicine (Baltimore)2016;95:e4529 PMCID:PMC4985329

[31] He L,Wang L.Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials.Medicine (Baltimore)2016;95:e4947 PMCID:PMC5079311

[32] Said A.Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.Ann Hepatol2017;16:538-47

[33] Armstrong MJ,Aithal GP.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.Lancet2016;387:679-90

[34] Newsome PN,Cusi K.NN9931-4296 InvestigatorsA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.N Engl J Med2021;384:1113-24

[35] Mantovani A,Beatrice G,Lonardo A.Glucagon-like Peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials.Metabolites2021;11:73 PMCID:PMC7911747

[36] Jia G,Wang Q.Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with Type 2 diabetes mellitus.PLoS One2015;10:e0142808 PMCID:PMC4643958

[37] Musso G,Tabibian JH.Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.PLoS Med2014;11:e1001680 PMCID:PMC4106719

[38] Singal AK,Kaif M,Kuo YF.Nonalcoholic steatohepatitis is the most rapidly growing indication for simulta- neous liver kidney transplantation in the United States.Transplantation2016;100:607-12

[39] Molnar MZ,Jiang Y.Association of pre-transplant renal function with liver graft and patient survival after liver trans- plantation in patients with nonalcoholic steatohepatitis.Liver Transplant2019;25:399-410

[40] Singal AK,Kaif M,Kuo YF.MELD stratified outcomes among recipients with diabetes or hypertension: simulta- neous liver kidney versus liver alone.J Clin Gastroenterol2018;52:67-72

[41] Vilar-Gomez E,Friedman SL.Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.Aliment Pharmacol Ther2017;45:332-44

[42] Musso G,Cohney S,Saba F.Emerging liver-kidney interactions in nonalcoholic fatty liver disease.Trends Mol Med2015;21:645-62

[43] Mizuiri S.ACE and ACE2 in kidney disease.World J Nephrol2015;4:74-82 PMCID:PMC4317630

[44] Morris E, Fletcher JA, Thyfault JP, Rector RS. The role of angiotensin II in nonalcoholic steatohepatitis.Mol Cell Endocrinol2013;378:29-40

[45] de Vries APJ,Ruan XZ.Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease.Lancet Diabetes Endocrinol2014;2:417-26

[46] Osterreicher CH,De Minicis S.Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice.Hepatology2009;50:929-38 PMCID:PMC4734904

[47] Cheungpasitporn W,O'Corragain OA,Kittanamongkolchai W.Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis.Nephrology (Carlton)2014;19:791-7

[48] Abdelmalek MF,Guy C.Nonalcoholic Steatohepatitis Clinical Research NetworkIncreased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease.Hepatology2010;51:1961-71 PMCID:PMC2922495

[49] Johnson RJ,Sanchez-Lozada LG.Sugar, uric acid, and the etiology of diabetes and obesity.Diabetes2013;62:3307-15 PMCID:PMC3781481

[50] Liabeuf S,Barreto FC.European Uraemic Toxin Work Group (EUTox)Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease.Nephrol Dial Transplant2010;25:1183-91

[51] Wu IW,Lee CC.p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease.Nephrol Dial Transplant2011;26:938-47 PMCID:PMC3042976

[52] Vaziri ND,Khazaeli M,Ichii H.Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption.Am J Nephrol2013;37:518-25 PMCID:PMC3777856

[53] Federico A,Masarone M,Loguercio C.The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction.Eur Rev Med Pharmacol Sci2016;20:4731-41

[54] Hamaguchi M,Takeda N.Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.World J Gastroenterol2007;13:1579-84 PMCID:PMC4146902

[55] Stepanova M.Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.Clin Gastroenterol Hepatol2012;10:646-50

[56] Sirota JC,Targher G,Chonchol M.Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.Metabolism2013;62:392-9 PMCID:PMC3565047

[57] Northup PG,Shah N.Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications.Semin Liver Dis2012;32:39-48

[58] Targher G.Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease.J Hepatol2006;45:879-81; author reply 881

[59] Oni ET,Blaha MJ.A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?.Atherosclerosis2013;230:258-67

[60] Sookoian S.Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review.J Hepatol2008;49:600-7

[61] Zheng J,Zhang K.Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old.BMC Cardiovasc Disord2018;18:147 PMCID:PMC6048911

[62] Brea A,Martín E,Cordero JL.Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study.Arterioscler Thromb Vasc Biol2005;25:1045-50

[63] Fracanzani AL,Raselli S.Carotid artery intima-media thickness in nonalcoholic fatty liver disease.Am J Med2008;121:72-8

[64] Cai J,Huang W.Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis.Int J Clin Exp Med2015;8:7673-8 PMCID:PMC4509261

[65] Chung GE,Kim D.Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index.Medicine (Baltimore)2015;94:e654 PMCID:PMC4554011

[66] Salvi P,Agnoletti D.Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study.J Hypertens2010;28:1699-707

[67] Lee YJ,Moon BS.The relationship between arterial stiffness and nonalcoholic fatty liver disease.Dig Dis Sci2012;57:196-203

[68] Gepner AD,Delaney JA.Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima-media thickness for cardiovascular disease prediction in the Multi-Ethnic Study of Atherosclerosis.Circ Cardiovasc Imaging2015;8:e002262 PMCID:PMC4299916

[69] Kim D,Park EH.Nonalcoholic fatty liver disease is associated with coronary artery calcification.Hepatology2012;56:605-13 PMCID:PMC3830979

[70] Park HE,Kim D,Cha MJ.Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study.J Clin Endocrinol Metab2016;101:3134-43

[71] Wong VW,Yip GW.Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease.Gut2011;60:1721-7

[72] Choi SY,Kim HJ.The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans.Am J Gastroenterol2009;104:1953-60

[73] Targher G,Lonardo A,Barbui C.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis.J Hepatol2016;65:589-600

[74] Ekstedt M,Nasr P.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology2015;61:1547-54

[75] Vilar-Gomez E,Wai-Sun Wong V.Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.Gastroenterology2018;155:443-457.e17

[76] VanWagner LB,Skaro AI,Rinella ME.Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.Liver Int2015;35:2575-83 PMCID:PMC5204362

[77] Vanwagner LB,Te HS,Alvarez L.Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events.Hepatology2012;56:1741-50

[78] Albeldawi M,Madhwal S.Cumulative risk of cardiovascular events after orthotopic liver transplantation.Liver Transpl2012;18:370-5

[79] Wannamethee SG,Shaper AG.The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes.Atherosclerosis2008;201:168-75

[80] Franzini M,Martinelli B.Gamma-glutamyltransferase activity in human atherosclerotic plaques--biochemical similarities with the circulating enzyme.Atherosclerosis2009;202:119-27

[81] Koenig G.Gamma-Glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk.Dis Markers2015;2015:818570 PMCID:PMC4620378

[82] Anstee QM,Tilg H.Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol2018;15:425-39

[83] Alonso A,Amiin MA.Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort.Heart2014;100:1511-6 PMCID:PMC4225783

[84] Sinner MF,Fox CS.Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation.Am J Cardiol2013;111:219-24 PMCID:PMC3538882

[85] Targher G,Bonapace S.Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes.PLoS One2013;8:e57183 PMCID:PMC3579814

[86] Targher G,Pichiri I.Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.Clin Sci (Lond)2013;125:301-9

[87] Wijarnpreecha K,Thongprayoon C,Ungprasert P.The association between non-alcoholic fatty liver disease and atrial fibrillation: A meta-analysis.Clin Res Hepatol Gastroenterol2017;41:525-32

[88] Mantovani A,Bergamini C.Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease.Metabolism2015;64:879-87

[89] Markus MR,Stritzke J.Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP).Arterioscler Thromb Vasc Biol2013;33:1690-5

[90] VanWagner LB,Colangelo LA.Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study.Hepatology2015;62:773-83 PMCID:PMC4549239

[91] Azzam H.Non-alcoholic fatty liver disease - the heart of the matter.World J Hepatol2015;7:1369-76 PMCID:PMC4450200

[92] Lee YH,Yoo ME.Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.J Hepatol2018;68:764-72

[93] Petta S,Colomba D.Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease.J Hepatol2015;62:928-33

[94] Simon TG,Chung RT,Corey KE.Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction.Obesity (Silver Spring)2017;25:1313-6 PMCID:PMC5648006

[95] Sato Y,Kanno Y.Liver stiffness assessed by Fibrosis-4 index predicts mortality in patients with heart failure.Open Heart2017;4:e000598 PMCID:PMC5471867

[96] Lin S,Wang M.Comparison of MAFLD and NAFLD diagnostic criteria in real world.Liver Int2020;40:2082-9

[97] Nguyen VH,Cheung RC.Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD.Clin Gastroenterol Hepatol2021;S1542-3565(21)00567:

[98] Sun DQ,Wang TY.MAFLD and risk of CKD.Metabolism2021;115:154433

[99] Niriella MA,Kasturiratne A.Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.PLoS One2021;16:e0245762 PMCID:PMC7857550

[100] Guerreiro GTS,Fonseca MA,Álvares-da-Silva MR.Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?.Hepatol Int2021;15:380-91

[101] Tsutsumi T,Kawaguchi T.MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach.Hepatol Res2021;

[102] Liu S,Wu S.The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis.Metabolism2021;120:154779

[103] Lee H,Kim SU.Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study.Clin Gastroenterol Hepatol2020;S1542-3565(20)31717:

[104] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[105] Brunner KT,Massaro JM,Benjamin EJ.Increasing liver fat is associated with progression of cardiovascular risk factors.Liver Int2020;40:1339-43

[106] Mantovani A,Beatrice G,Byrne CD.Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.Gut2021;70:962-9

[107] Huang J,Wang M,Lin S.MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?.J Hepatol2020;73:1265-7